Brazilian hospital study indicates arthritis drug reduces Covid-19 risk of death by 37%

The findings were published on Wednesday, June 16, in The New England Journal of Medicine. The drug has not been approved by any national health regulatory agency.

RIO DE JANEIRO, BRAZIL - A study, conducted by researchers at the Hospital Israelita Albert Einstein in São Paulo, of a drug for rheumatoid arthritis from Pfizer pharmaceutical company, showed that the medication, able to modulate the immune system, reduced by 37% the risk of death or respiratory failure in patients with moderate symptoms hospitalized with Covid-associated pneumonia.

The findings were published on Wednesday, June 16, in The New England Journal of Medicine.

The study began in October last year and the medication used was Tofacitinib, sold under the trade name Xeljanz, which showed an impact on cytokine storm . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?